• Profile
Close

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: Systematic review of clinical and experimental evidence with special emphasis on ovarian cancer

Archives of Gynecology and Obstetrics Evidence based | Jun 07, 2018

Tempfer C, et al. - Researchers investigated if intraperitoneal chemotherapy could be an alternative to systemic chemotherapy and cytoreductive surgery for patients with peritoneal carcinomatosis (PC). Via performing a systematic review of clinical and experimental evidence on the safety and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with PC, they recognized PIPAC as feasible, safe, and effective. In patients with recurrent cancer and PC, PIPAC maintains quality of life. In women with ovarian cancer and PC, PIPAC is as evidence-based as any other treatment beyond the third line of systemic chemotherapy and can be recommended in this indication.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay